Sino biopharmaceutical begins clinical trials for innovative cancer therapy

Sino Biopharmaceutical Limited announced the successful enrollment of the first patient in the Phase I clinical trial of LM-350 “CDH17 antibody-drug conjugate (ADC)” in Australia. This marks the official entry into clinical development for the national class 1 innovative drug, developed by LaNova Medicines Limited, a wholly-owned subsidiary of the company.

LM-350, developed using LaNova Medicines' LM-ADCTM platform, targets CDH17 and has demonstrated strong anti-tumor activity in preclinical studies across various xenograft models, including colorectal cancer cells resistant to MMAE or Irinotecan. The clinical study is an open-label, dose escalation and dose expansion Phase I/II trial evaluating the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy in patients with advanced solid tumors.

CDH17 plays a critical role in tumor invasion and metastasis, with high expression in various gastrointestinal cancers, including approximately 99% of colon cancers and 86% of gastric adenocarcinomas. Gastrointestinal tumors represent a significant unmet clinical need, with over 4m new patients reported globally in 2022.